Innovation New Jersey
  • Home
  • Our Coalition
    • Contact Us
  • News
  • Resources
    • State Supports
    • Federal Supports
    • Higher Ed Supports
  • Join Us

Innovation News

Everything Innovation. Everything New Jersey.
Follow us and stay connected.

Patent Reform Comes Roaring Back to Life After a Lazy Summer

9/7/2015

0 Comments

 
Washington D.C. - According to Michael Rosen of the American Enterprise Institute, "Like most of us, legislative patent reform spent the summer on the beach. But as the congressional session resumes next week, the vacation is coming to an end. Shortly before adjourning for its summer recess, the House of Representatives shelved – at least temporarily – the Innovation Act, its signature patent reform legislative package amidst strident opposition from the biotechnology industry, academic and research institutions, and venture capital investors."
Several members who previously supported the legislation announced a change of heart, and House leadership had no choice but to pull the bill. A companion measure in the Senate, known as the PATENT Act, also had an indolent summer, failing to advance since its passage by the chamber’s Judiciary Committee.

But now, as summer turns to fall, and as members return to the Capitol, the patent wars are again beginning to heat up among interest groups.

The National Retail Federation, which has long backed the various reform measures, has set September 10 as a “day of Capitol Hill meetings to demand that Congress try again to pass litigation reform.”

On the other end of the spectrum, the Conservative Action Program, an umbrella group comprising, among others, former Reagan Attorney General Ed Meese, former Ohio Secretary of State Ken Blackwell, and former Virginia Attorney General Ken Cuccinelli, urged Congress to “stand up for our constitutionally protected patent rights and reject another Washington ‘fix.’”

Meanwhile, the life sciences industry, which largely opposes both the Innovation Act and the PATENT Act, has instead pushed for relief from a number of new Patent Office proceedings inaugurated by the last round of patent legislation: 2011’s America Invents Act.

These proceedings were meant to be less costly and time consuming alternatives to the classic in-depth patent litigation. Most prominent among the new proceedings is a process called “inter partes review” (IPR), in which a patent’s validity can be challenged under a lower burden of proof, through a broader reading of the patent’s language, and via a cheaper, faster review.

As I explained earlier this year, the advent of these proceedings over the past several years – which have shown more than 200 percent growth year-over-year – has sharply reduced the number of patent cases brought in court. Pharmaceutical companies have increasingly bridled at IPR and its sister proceedings, especially as unlikely interlocutors like hedge funds have gotten in on the action.

Specifically, in April, the Wall Street Journal reported that hedge fund manager Kyle Bass had filed IPRs against patents held by Jazz Pharmaceuticals, Acorda Therapeutics, and Shire, soon thereafter supposedly shorting their stock and taking positions in rival generic drugmakers. Bass’s group has since added Celgene and Biogen to its target list. Other hedge funds have followed suit.

But the biotech industry has fought back on multiple fronts. The STRONG Patents Act, introduced in the Senate in March, would, among other things, raise the burden of proof and tighten the standard for interpreting claims in IPR and other proceedings in order to re-level the playing field. Some, but not all, of those provisions found their way into the Senate’s PATENT Act; none has yet been integrated into the Innovation Act.

And thus pharma companies have also turned to a second strategy: securing an exemption for biotech patents from IPR. Since the Patent Office proceedings were designed primarily to weed out bad software and business-method patents, they reckon pharma patents probably shouldn’t have been subjected to their rigors in the first place.

But in July, according to the Wall Street Journal, the Congressional Budget Office scored this proposal and preliminarily found it would increase federal spending by $1.3 billion over the course of 10 years since it would delay the emergence of cheaper generic drugs. Tom DiLenge, general counsel of the Biotechnology Industry Organization, responded that the CBO’s premises were flawed, as “IPR is not designed to speed generic entry,” and that, in any event, $130 million per year represents a fairly small impact.

So expect this debate over IPR, pharma, and the remainder of the legislative package to intensify as Congress returns to session next week.

And finally, a plug: as the patent reform debate resumes, AEI has you covered. If you find yourself in DC next week, join us at the Institute on Tuesday for a lunchtime panel discussion among distinguished experts, moderated by yours truly, on the various legislative proposals and their prospects for passage.

- See more at: http://www.techpolicydaily.com/technology/patent-reform-roaring-back/?utm_source=newsletter&utm_medium=paramount&utm_campaign=cict#sthash.nD8aYPhg.dpuf

0 Comments



Leave a Reply.

    Do not miss a single innovative moment and sign up for our newsletter!
    Weekly updates


    Categories

    All
    3D Printing
    Academia
    Acquisitions
    Aerospace
    Agriculture
    AIDS
    Algae
    Alumni
    Animals
    Architecture
    Astrophysics
    Autism
    Awards
    Big Data
    Bioethics
    Biofuel
    Biomedical
    BioNJ
    Bioterrorism
    Bit Coins
    Brain Health
    Business
    Camden
    Cancer
    CCollege
    Cellular
    Centenary
    Chemistry
    ChooseNJ
    Climate Change
    Clinical Trials
    Cloud Tech
    Collaboration
    Computing
    Congress
    Coriell
    Council On Innovation
    Crowdfunding
    Cybersecurity
    DARPA
    Defense
    Degree
    Dementia
    Dental Health
    DOC
    DOD
    DOE
    Drew
    Drones
    Drug Creation
    Einstein's Alley
    Electricity
    Energy
    Engineering
    Entrepreneurship
    Environmental
    FAA
    Fairleigh Dickinson
    FDA
    Federal Budget
    Federal Government
    Federal Labs
    Federal Program
    Finance
    Food Science
    Fort Monmouth
    Fuel Cells
    Funding
    Genome
    Geography
    Geology
    Global Competition
    Google
    Governor Christie
    Grant
    Hackensack
    HackensackUMC
    Healthcare
    Health Care
    HHS
    HINJ
    Hospitals
    Immigration
    Incubator
    Infrastructure
    International
    Internet
    Investor
    IoT
    IP
    IT
    Jobs
    Johnson & Johnson
    K-12
    Kean
    Kessler
    Legislation
    Logistics
    Manufacturing
    Medical Devices
    Med School
    Mental Health
    Mentor
    Microorganisms
    Molecular Biology
    Montclair
    NAS
    Neuroscience
    Newark
    New Jersey
    NIFA
    NIH
    NIST
    NJBDA
    NJBIA
    NJ Chemistry Council
    NJCU
    NJDOLWD
    NJEDA
    NJEDge
    NJHF
    NJII
    NJIT
    NJMEP
    NJPAC
    NJPRO
    NJTC
    Nonprofit
    NSF
    OpEd
    Open Data
    OSHE
    OSTP
    Parasite
    Patents
    Paterson
    Patients
    Perth Amboy
    Pharma
    POTUS
    PPPL
    Princeton
    Prosthetics
    Ranking
    Rare Disease
    R&D Council
    Report
    Resiliency
    Rider
    Robotics
    Rowan
    Rutgers
    SBA
    Seton Hall
    Siemens
    Smart Car
    Smart Cities
    Software
    Solar
    Space
    SSTI
    Startup
    State Government
    STEM
    Stevens
    Stockton
    Subatomic
    Supports
    Sustainability
    Taxes
    TCNJ
    Teachers
    Telecom
    Therapy
    Thermodynamics
    Transportation
    Undergraduate
    USEDA
    Verizon
    Video Game
    Virtual Reality
    Water
    WHO
    William Paterson
    Women In STEM
    Workforce Development

Home   Coalition   News   Resources   Events   Join Us
Picture
Innovation New Jersey Coalition
10 West Lafayette Street
Trenton, NJ 08608-2002
609-858-9507